Sensors for Medicine and Science (SMSI), which is developing an implantable glucose monitoring sensor, announced this week that it received $54.1 million in fourth round funding. Delphi Ventures led the investment, which also included contributions from return backers New Enterprise Associates (NEA), HealthCare Ventures, Anthem Capital and Greenspring Associates.
The company plans to use the...
Echo Therapeutics, creator of a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system called Symphony and a transdermal drug delivery system called Prelude SkinPrep, recently debuted a demonstration video on its company website, reports MedGadget. The new video showcases the use of the Symphony system in a home setting and coincides with an upcoming clinical study.
The...
3M Health Information Systems and IQMax expand deal: The companies plan to develop services that improve physician workflow, streamline revenue cycle processes, and provide instant access to critical information to support patient care. 3M branded mobile apps for charge capture and others that efficiently help physicians meet documentation requirements under ICD-10 will also come out of the newly...
Telus health in Canda: Cisco Canada: "In the space of one year, many health-care executives have gone from being unsure about wireless as a primarily delivery mode for network access to clinical and administrative applications to being convinced it's the route to go." Calgary Herald
Lactic acid monitoring: Echo Therapeutics, which has developed a wireless, non-invasive transdermal continuous...
Scientific American recently published a feature on wireless enabled and needle-free, continuous blood glucose monitoring company Echo Therapeutics, which was one of the few startups in wireless health that announced venture capital investment last year. Echo is currently seeking NDA clearance from the FDA. According to Scientific American, Echo's offering, Symphony tCGM, has three distinct...
CGM start-up raises $3M: Echo Therapeutics, which is developing a needle-free, non-invasive, wireless, transdermal continuous glucose monitoring system and and a system for transdermal drug delivery, raised $3 million in additional capital by selling common stock to accredited and institutional investors. More
Medtronic points to studies lauding CGM: “It’s very exciting to see the evidence unfold...
